TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Average preoperative AI grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for interval valve replacement
Endpoint domain: Adverse events/effects
Primary endpoint: Severe PONV
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in vein size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in QF strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramp duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Satisfaction of parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: average INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fraction of INR in therapeutic range (2‐3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WLRT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative allogeneic blood component transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Inspiratory Pressures (PIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fraction of Inspired Oxygen (FiO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial Pressure of CO2 (PCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Achieved goal BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HSV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total duration of action of mivacurium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time following neostigmine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major CIED infections
Endpoint domain: Adverse events/effects
Primary endpoint: on-task behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of large groin haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: 14-day adverse vascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Fracture incidence in postmenopausal women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ABC-Irritability total subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC Stereotypic Behavior total subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC Hyperactivity total subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qmax improvement in BPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of response at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use of Ventolin Rotacaps as rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: High-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SR peak normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sneezing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bucking score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allogenic platelet transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of local regional recurrence at 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SBF (Skin Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to next recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration until RTW
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Phosphate intake adjustment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ≥75% pigmentation on the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ≥75% pigmentation on the limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ≥75% pigmentation on the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: new breast cancer event
Endpoint domain: Mortality/survival
Primary endpoint: Up&go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10‐m walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment on delayed pattern recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of malignant arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: BWAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urethral catheterization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AAI (Anesthetic Depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain syndrome intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR-neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CR-IM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence of neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean serum GGT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PSQI scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Oxygen uptake at estimated anaerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake at Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-exercise phosphocreatine recovery rate constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ̇VO(2)max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global worst score for local tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: suppression of AIX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aesthetic outcomes following ear reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with clinical outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of time within target plasma glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HPS (High-Grade Stenosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke event rate (minor and/or major stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Restenosis rate
Endpoint domain: Mortality/survival
Primary endpoint: Stroke or TCI
Endpoint domain: Mortality/survival
Primary endpoint: doses required to achieve target levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rejection rates
Endpoint domain: Mortality/survival
Primary endpoint: logMAR BCVA at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of secondary reattachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of cataract progression
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III/IV toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Total doses of fentanyl administered during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total doses of intravenous morphine administered in the postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain score at the time of admission and maximum pain score during stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bone nonunion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of avascular necrosis of the femoral head
Endpoint domain: Adverse events/effects
Primary endpoint: Time of rehabilitation and weight-loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage increase in NFD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurite outgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reported acquisitive crimes
Endpoint domain: Adverse events/effects
Primary endpoint: visceral pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a complete response during the 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with nausea during the 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with vomiting during the 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hazard ratios for dose points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shoulder-related disability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: experimental pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts prior to successful tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio for combination arm vs control arm
Endpoint domain: Mortality/survival
Primary endpoint: dynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vestibular and somatosensory integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of fall
Endpoint domain: Adverse events/effects
Primary endpoint: Development of adverse LV remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of atomoxetine
Endpoint domain: Adverse events/effects
Primary endpoint: Normalized ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade point average in STEM courses
Endpoint domain: Life impact
Endpoint subdomain: Academic performance
Primary endpoint: ADP-induced platelet inhibition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom remission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total plasma p‐cresol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: distance between the center of the target vessel and the needle tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cataract surgery requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of posterior subcapsular cataract
Endpoint domain: Adverse events/effects
Primary endpoint: Mean visual acuity after cataract surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting QTd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta QTd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of working die dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients clinically cured at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with negative fungal cultures at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with severe symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of neonatal jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up care seeking
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bilirubin measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: naming latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function response to ACh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasoconstrictor response to LNMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coupon redemption rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: visual short-term memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: verbal working memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: executive control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BE days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week BE cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical recurrence-free survival (BCDF)
Endpoint domain: Mortality/survival
Primary endpoint: Duration of IV antimicrobial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeliness of switch to oral antimicrobials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of intraarticular methylprednisolone injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TWA amplitude reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Life (QOL) differences
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NICU admissions for hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient neonatal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days in the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall length of hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expiratory reserve volume (ERV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contrast enhancement values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective image noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of time with intragastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean time to progression
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to cancer related death
Endpoint domain: Mortality/survival
Primary endpoint: Mean overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Bone mineral density loss over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non-fatal overdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial tissue pyruvate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactate/pyruvate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chlamydia positivity rate at retest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ex vivo thrombus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tissue-type plasminogen activator release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No longer meet PTSD diagnostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieve total remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the incidence of nosocomial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Feelings of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuropsychological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved patient outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ischemic heart disease (IHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vWF (von Willebrand Factor) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: muscle venous O(2) hemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracellular muscle pH (pHi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integrated lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insomnia scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: appendicular skeletal muscle mass (ASMM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Requirement for renal replacement therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean changes in VAS for walking pain, standing pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lequesne's functional index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Spinal Cord Injury Association motor score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: degree of bother of symptoms postpartum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of PFO using CFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of iodine deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ciliary beat frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effective sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weight loss at 5 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heavy relapse rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: CHEOPS score at 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHEOPS scores for the first eight postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first postoperative rescue analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S. mutans population in subgingival and supragingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total severity score of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amount of antacid used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean serum selenium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of first successful nasotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of successful intubation under conscious condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of difficult intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of catheter-related bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: less disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Verbal learning and memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social cognition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm morphology and forward progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Confirmed tuberculosis development
Endpoint domain: Mortality/survival